CD8A and neoplasm: For instance, ‘cancer-testis’ antigen NY-ESO-1 was identified by SEREX in oesophageal cancer and is regarded as one of the most immunogenic tumour antigens; antibody responses to NY-ESO-1 have been observed in 40–50% of patients with NY-ESO-1 expressing tumours and antibody production strongly correlates with CD8+ T cell responses in these patients (Jager et al, 2000c).